GLP-1s vs Bariatric Surgery; Obesity Trends Reversing; Creatine for Menopause?

GLP-1 medication use increased by 140.4% from 2022 to 2024 while metabolic bariatric surgery utilization declined by 34.1%, national insurance data indicated. (JAMA Surgery)

Generic forms of semaglutide (Ozempic, Wegovy) aren’t expected in the U.S. until at least 2031, despite being available in other countries. (NBC News)

A global analysis found long-rising obesity trends have finally slowed, stabilized, or even slightly reversed in many high-income nations. (Nature)

The European Association for the Study of Obesity updated its framework for anti-obesity medications, advising clinicians to look beyond weight loss alone and use a personalized approach to prescribing. (Nature Medicine)

Osteoporosis was linked to a 47% increased risk of all-cause death in postmenopausal women, according to national data. (Menopause)

Retinal photographs may offer a simple, non-invasive, and accessible way to support opportunistic screening for osteoporosis risk, researchers wrote in PLOS Digital Health.

Could creatine help women maintain muscle mass through menopause? (New York Times)

After 60 weeks on maximally tolerated tirzepatide (Zepbound), patients who continued on the same dose preserved all prior weight loss, while those who reduced their dose to 5 mg maintained all but 12.3 lb, the SURMOUNT-MAINTAIN trial showed. (The Lancet)

Meanwhile in ATTAIN-MAINTAIN, patients who transitioned from injectable semaglutide or tirzepatide to the oral GLP-1 receptor agonist orforglipron (Foundayo) maintained between 75% and 79% of their prior weight loss after 1 year. (Nature Medicine)

Axios looked at how GLP-1 medications are changing how brides shop for wedding dresses.

Cardiovascular health declined in women from pre- to postmenopause, with the lowest scores on the American Heart Association’s Life’s Essential 8 reported during perimenopause. (Journal of the American Heart Association)

Mobile health technologies targeted at managing type 1 diabetes in resource-limited settings were cost-effective, provided there was a basic supporting infrastructure. (Lancet Diabetes & Endocrinology)

Participants treated with an investigational oral GLP-1/GIP agonist (VK2735) lost up to 12.2% of mean body weight (26.6 lb) by week 13 without a plateau in a phase II trial, said developer Viking Therapeutics.

The investigational triple agonist retatrutide was tied to improvements in fatty acid oxidation and insulin resistance in participants with obesity, regardless of diabetes status. (Journal of Clinical Endocrinology & Metabolism)